个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial.

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Jiang Tao[1] ; Chen Jianhua[2] ; Xu Xingxiang[3] ; Cheng Ying[4] ; Chen Gongyan[5] ; Pan Yueyin[6] ; Fang Yong[7] ; Wang Qiming[8] ; Huang Yunchao[9] ; Yao Wenxiu[10] ; Wang Rui[11] ; Li Xingya[12] ; Zhang Wei[13] ; Zhang Yanjun[14] ; Hu Sheng[15] ; Guo Renhua[16] ; Shi Jianhua[17] ; Wang Zhiwu[18] ; Cao Peiguo[19] ; Wang Donglin[20] ; Fang Jian[21] ; Luo Hui[22] ; Geng Yi[23] ; Xing Chunyan[24] ; Lv Dongqing[25] ; Zhang Yiping[26] ; Yu Junyan[27] ; Cang Shundong[28] ; Zhang Yaxi[29] ; Zhang Jiao[29] ; Yang Zeyu[30] ; Shi Wei[30] ; Zou Jianjun[30] ; Zhou Caicun[1] ; Ren Shengxiang[1] ;
机构： [1]Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, No.507, Zhengmin Road, Shanghai, 200433, China. [2]Hunan Cancer Hospital, Changsha, China. [3]Northern Jiangsu People's Hospital, Yangzhou, China. [4]Jilin Cancer Hospital, Changchun, China. [5]Harbin Medical University Cancer Hospital, Harbin, China. [6]Anhui Provincial Hospital, Hefei, China. [7]Sir Run Run Shaw Hospital Zhejiang University School of Medicine, Hangzhou, China. [8]Henan Cancer Hospital, Zhengzhou, China. [9]Yunnan Cancer Hospital &The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Centre, Kunming, China. [10]Sichuan Provincial Cancer Hospital, Chengdu, China. [11]Anhui Chest Hospital, Hefei, China. [12]The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. [13]The First Affiliated Hospital of Nanchang University, Nanchang, China. [14]Shaanxi Provincial Cancer Hospital, Xi'an, China. [15]Hubei Cancer Hospital, Wuhan, China. [16]Jiangsu Province Hospital, Nanjing, China. [17]LinYi Cancer Hospital, Linyi, China. [18]Tangshan People's Hospital, Tangshan, China. [19]The Third Xiangya Hospital of Central South University, Changsha, China. [20]Chongqing University Cancer Hospital, Chongqing, China. [21]Beijing Cancer Hospital, Beijing, China. [22]Jiangxi Cancer Hospital, Nanchang, China. [23]Baoji Central Hospital, Baoji, China. [24]Jinan Central Hospital, Jinan, China. [25]Taizhou Hospital of Zhejiang Province, Taizhou, China. [26]Zhejiang Cancer Hospital, Hangzhou, China. [27]Heping Hospital Affiliated to Changzhi Medical College, Changzhi, China. [28]Henan Provincial People's Hospital, Zhengzhou, China. [29]Genecast Biotechnology Co., Ltd., Wuxi City, China. [30]Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China
出处：
DOI： 10.1186/s12943-021-01479-4
ISSN：

摘要：
Camrelizumab plus chemotherapy significantly prolonged progression-free survival (PFS) and overall survival (OS) compared to chemotherapy alone as first-line treatment in advanced lung squamous cell carcinoma (LUSC) in the phase III trial (CameL-sq), which has become an option of standard-of-cares for Chinese patients with advanced LUSC. However, the predictive biomarkers remain unknown.Tumor tissue samples at baseline, and peripheral blood samples at baseline (pretreatment) and after two cycles of treatment (on-treatment) were prospectively collected from 270 LUSC patients from the CameL-sq study. Blood tumor mutation burden (bTMB) and its dynamics were analyzed to explore their predictive values.Pretreatment bTMB was not associated with objective response, PFS and OS in camrelizumab or placebo plus chemotherapy groups. Low on-treatment bTMB was associated with significantly better objective response (73.8% vs 27.8%, P < 0.001), PFS (median, 9.1 vs 4.1 months; P < 0.001) and OS (median, not reached vs 8.0 months; P < 0.001) in camrelizumab plus chemotherapy group whereas it did not correlate with objective response and PFS in chemotherapy alone group. Importantly, on-treatment bTMB level could discriminate patients of initially radiological stable disease who would long-term benefit from camrelizumab plus chemotherapy (low vs high, median OS, 18.2 vs 7.8 months; P = 0.001). Combing on-treatment bTMB and its dynamics improved the ability for predicting the efficacy of camrelizumab plus chemotherapy.On-treatment bTMB together with its dynamics could serve as a predictive biomarker for camrelizumab plus chemotherapy in patients with advanced LUSC.ClinicalTrials.gov identifier: NCT03668496.© 2021. The Author(s).

基金：
This study was also supported in part by grants from the National Natural Science Foundation of China (No. 81871865, 81874036, 81972167 and 82102859), the Backbone Program of Shanghai Pulmonary Hospital (No. FKGG1802), Shanghai Pujiang Talent Plan (No. 2019PJD048), Shanghai Science and Technology Committee Foundation (NO. 19411950300), Shanghai Key disciplines of Respiratory (No. 2017ZZ02012), Oncology development incentive program of Shanghai Pulmonary Hospital, Shanghai Multidisciplinary Cooperative Project for Diagnosis and Treatment of Major Diseases, and Key Clinical Project Development Program of Shanghai.
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 生化与分子生物学
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 生化与分子生物学 1 区 肿瘤学
JCR分区：
出版当年[2022]版：
Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Q1 ONCOLOGY
最新[2023]版：
Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者：
第一作者机构： [1]Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, No.507, Zhengmin Road, Shanghai, 200433, China.
通讯作者：
推荐引用方式(GB/T 7714)：
Jiang Tao,Chen Jianhua,Xu Xingxiang,et al.On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial.[J].MOLECULAR CANCER.2022,21(1):doi:10.1186/s12943-021-01479-4.
APA：
Jiang Tao,Chen Jianhua,Xu Xingxiang,Cheng Ying,Chen Gongyan...&Ren Shengxiang.(2022).On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial..MOLECULAR CANCER,21,(1)
MLA：
Jiang Tao,et al."On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial.".MOLECULAR CANCER 21..1(2022)

资源点击量：43377 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号